NASDAQ · BBIO
Healthcare · Biotechnology
$82.98
Up+$3.09 (+3.87%)
Updated Aug 19, 2026, 8:31 AM
SID Score
6.7/10
Composite research score
Smart Money
59/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
BBIO closed at $82.98 after 21 trading sessions, up 0.64% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $80.54 | $83.95 | $80.10 | $82.98 | 2.72M |
| Aug 17, 2026 | $79.15 | $80.42 | $78.125 | $79.89 | 2.8M |
| Aug 14, 2026 | $80.14 | $80.56 | $78.60 | $79.86 | 3.09M |
| Aug 13, 2026 | $84.77 | $84.77 | $80.78 | $81.21 | 1.28M |
| Aug 12, 2026 | $83.47 | $84.99 | $82.82 | $83.84 | 2.79M |
| Aug 11, 2026 | $87.02 | $89.49 | $83.35 | $83.70 | 3.08M |
| Aug 10, 2026 | $83.45 | $86.00 | $83.45 | $84.67 | 2.94M |
| Aug 7, 2026 | $83.72 | $85.03 | $82.24 | $84.48 | 2.15M |
| Aug 6, 2026 | $81.50 | $84.655 | $81.50 | $82.80 | 1.22M |
| Aug 5, 2026 | $82.86 | $83.57 | $81.46 | $81.99 | 2.42M |
| Aug 4, 2026 | $80.80 | $82.32 | $80.035 | $82.07 | 1.7M |
| Aug 3, 2026 | $81.23 | $81.23 | $78.82 | $79.96 | 1.37M |
| Jul 31, 2026 | $82.38 | $82.40 | $79.455 | $80.09 | 2.13M |
| Jul 30, 2026 | $80.06 | $82.41 | $79.60 | $82.14 | 2.52M |
| Jul 29, 2026 | $85.49 | $85.785 | $83.35 | $83.54 | 2.4M |
| Jul 28, 2026 | $84.24 | $85.66 | $83.02 | $85.55 | 2.18M |
| Jul 27, 2026 | $84.105 | $86.32 | $83.98 | $84.12 | 2.19M |
| Jul 24, 2026 | $83.46 | $85.30 | $82.74 | $84.02 | 2.06M |
| Jul 23, 2026 | $82.40 | $83.53 | $81.77 | $82.93 | 1.53M |
| Jul 22, 2026 | $82.47 | $82.88 | $81.02 | $82.66 | 1.57M |
| Jul 21, 2026 | $80.80 | $82.61 | $80.76 | $82.45 | 1.39M |
The latest Smart Investors Daily articles mentioning BBIO.
BBIO research
Company profile and research snapshot.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Canaccord Genuity | Buy | — |
| Aug 12, 2026 | Truist Securities | Buy | — |
| Aug 12, 2026 | JP Morgan | Overweight | — |
| Aug 11, 2026 | Wells Fargo | Overweight | — |
| Aug 11, 2026 | Piper Sandler | Overweight | — |
No generated briefing is available yet.
Benzinga · Aug 13, 2026
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the launch of a secondary
Benzinga · Aug 12, 2026
Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $102 to $107.
Benzinga · Aug 12, 2026
Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $104 to $106.
Benzinga · Aug 12, 2026
JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $100 to $111.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BBIO.
